The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!

Industry pessimistic expectations may improve.

Gelonghui FinanceDec 8 23:10 ET

How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.

① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.

cls.cnDec 8 03:48 ET

Mabpharm Limited (HKG:2181) Adds HK$392m in Market Cap and Insiders Have a 50% Stake in That Gain

Simply Wall StSep 30 18:46 ET

MABPHARM-B: 2024 Interim Report

HKEXSep 24 04:35 ET · Announcements

Express News | Mabpharm H1 Revenue RMB 108.5 Million

ReutersAug 28 07:27 ET

MABPHARM-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024

HKEXAug 28 07:27 ET · Announcements